Anugerah 88 Logo
$10.71-0.22|(-2.01%)
52W H: 309.652W L: 9.1Beta: 2.28

About Gossamer Bio Inc

Frequently Asked Questions

What is the 52-week range for GOSS?

The 52-week high is $309.6 and the 52-week low is $9.1.

What is the P/E ratio for GOSS?

The P/E ratio data is currently unavailable.

What is the dividend yield for GOSS?

This company does not currently pay a dividend or the data is unavailable.

What is the Return on Equity (ROE)?

The trailing twelve months (TTM) Return on Equity is -118.77%.

What is the Net Profit Margin?

The Net Profit Margin (TTM) is -235.00%.

What is the Price to Book (P/B) Ratio?

The annual Price to Book ratio stands at 6.95.

Analyst Recommendation Trends

Wall Street analyst consensus for GOSS over the last few months:

2026-09-01
Buy: 6
S.Buy: 3
Hold: 4
Sell: 1
2026-08-01
Buy: 6
S.Buy: 3
Hold: 4
Sell: 1
2026-07-01
Buy: 6
S.Buy: 2
Hold: 5
Sell: 1
2026-06-01
Buy: 6
S.Buy: 2
Hold: 5
Sell: 1

Latest GOSS News

Gossamer Bio (GOSS) Stock Draws Fresh Price Target Split Before Seralutinib NDA

Gossamer Bio’s modeled fair value has shifted from US$1.66 to US$82.48, reflecting the 1 for 80 reverse stock split and refreshed valuation work. Street research links these reset price targets to a split view on risk and reward for seralutinib as it moves toward a planned PAH NDA submission, with analysts weighing FDA feedback, trial data and single asset concentration. As you read on, you will see how to track these changing targets and what might matter most for following the evolving...

Yahoo10/1/2026

Curious about the stocks that are showing activity after the closing bell on Friday?

Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.

ChartMill9/25/2026

12 Health Care Stocks Moving In Friday's After-Market Session

Gainers Onconetix (NASDAQ:ONCO) stock increased by 10.3% to $1.14 during Friday's after-market session. The market value of their outstanding shares is at $3.9 million. Bullfrog AI Hldgs (NASDAQ:BFRG) shares moved

Benzinga9/25/2026

Gossamer Bio Submits New Drug Application to U.S. FDA for Seralutinib for the Treatment of Pulmonary Arterial Hypertension

SAN DIEGO, September 23, 2026--Gossamer Bio, Inc. (Nasdaq: GOSS) (the "Company" or "Gossamer"), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that it submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in September 2026 for seralutinib for the treatme

Yahoo9/23/2026

Gossamer Bio Submits NDA To FDA For Seralutinib For Treatment Of Pulmonary Arterial Hypertension

– NDA Supported by the Phase 3 PROSERA Study, Phase 2 TORREY Study and Additional Supportive Analyses –Gossamer Bio, Inc. (NASDAQ:GOSS) (the "Company" or "Gossamer"), a clinical-stage biopharmaceutical

Benzinga9/23/2026

HC Wainwright & Co. Maintains Buy on Gossamer Bio, Raises Price Target to $90

HC Wainwright & Co. analyst Patrick R. Trucchio maintains Gossamer Bio (NASDAQ:GOSS) with a Buy and raises the price target from $2 to $90.

Benzinga9/21/2026

Gossamer Bio Appoints Greg Ciongoli to Board of Directors

SAN DIEGO, September 16, 2026--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that Greg Ciongoli has been appointed to the Company's Board of Directors, effective September 16, 2026. Mr. Ciongoli will also serve as a member of the Audit Committee.

Yahoo9/16/2026

Gossamer Bio Announces Effectiveness of 1-for-80 Reverse Stock Split

SAN DIEGO, September 11, 2026--Gossamer Bio, Inc. (Nasdaq: GOSS) (the "Company" or "Gossamer"), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease, today announced that it has filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware to

Yahoo9/11/2026

Gossamer Bio Announces 1-for-80 Reverse Stock Split

SAN DIEGO, September 09, 2026--Gossamer Bio, Inc. (Nasdaq: GOSS) (the "Company" or "Gossamer"), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease, today announced that its board of directors (the "Board") has selected a 1-for-80 reverse stock split of the Company’s common stock and a proportionate reduction in the numbe

Yahoo9/9/2026

Gossamer Bio Announces 1-For-80 Reverse Stock Split, Effective September 10

Gossamer Bio, Inc. (NASDAQ:GOSS) (the "Company" or "Gossamer"), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary

Benzinga9/9/2026

Assessment of the Pulmonary Arterial Hypertension (PAH) Market 2026-2036 Featuring United Therapeutics, Mochida Pharmaceutical, Johnson & Johnson, Merck, and Gossamer Bio

Dublin, Sept. 08, 2026 (GLOBE NEWSWIRE) -- The "Pulmonary Arterial Hypertension - Market Insight, Epidemiology, and Market Forecast - 2036" has been added to ResearchAndMarkets.com's offering. The pulmonary arterial hypertension (PAH) market across the United States, EU4 countries-Germany, France, Italy, and Spain-the United Kingdom, and Japan reached approximately USD 8 billion in 2025. The market is projected to expand at a compound annual growth rate of 6.7% from 2022 to 2036, supported by ri

Yahoo9/8/2026

Gossamer Bio to Present at Cantor Global Healthcare Conference

SAN DIEGO, September 04, 2026--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Company will present at the Cantor Global Healthcare Conference to take place on September 9-11, 2026.

Yahoo9/4/2026

Related Stocks (Peers)

Companies operating in similar sectors to GOSS:

XBITAPLMFBIONMADHRTXGOSSFRMMINKTACETBOLDKLRSCNTB950160.KQ

Recent Insider Transactions

DateNameShares ChangedPriceValue
2026-09-23Milligan Sandra+10,000--
2026-09-23Ciongoli Gregory Austin+30,000--
2026-09-23Drynan Skye+10,000--
2026-09-23Nathan Steven D+10,000--
2026-09-23Quisel John D+10,000--
2026-09-23Daniel Thomas O+10,000--
2026-09-23Cox Russell J.+10,000--
2026-08-24Smith Robert Paul JR+5,800,051--
2026-08-24Peterson Caryn+5,800,051--
2026-08-24Giraudo Bryan+5,800,051--
2026-08-24Giraudo Bryan+25$999.999$25,000
2026-08-24Christian Waage+2,900,026--
2026-08-24Hasnain Faheem+5,800,051--
2026-08-24Hasnain Faheem+166$999.999$166,000
2026-06-04Nathan Steven D+115,000--
2026-06-04Drynan Skye+115,000--
2026-06-04Milligan Sandra+115,000--
2026-06-04Quisel John D+115,000--
2026-06-04Daniel Thomas O+115,000--
2026-06-04Cox Russell J.+115,000--
2026-03-19Smith Robert Paul JR+572,000--
2026-03-19Smith Robert Paul JR+562,500--
2026-03-19Smith Robert Paul JR-572,000--
2026-03-19Smith Robert Paul JR-562,500--
2026-03-19Aranda Richard+30,000--
2026-03-19Aranda Richard+9,167--
2026-03-19Aranda Richard+22,784--
2026-03-19Aranda Richard+40,000--
2026-03-19Aranda Richard+20,000--
2026-03-19Aranda Richard+126,667--
2026-03-19Aranda Richard+157,500--
2026-03-19Aranda Richard+157,500--
2026-03-19Aranda Richard+162,500--
2026-03-19Aranda Richard+487,500--
2026-03-19Aranda Richard+572,000--
2026-03-19Aranda Richard+562,500--
2026-03-19Aranda Richard-30,000--
2026-03-19Aranda Richard-9,167--
2026-03-19Aranda Richard-22,784--
2026-03-19Aranda Richard-40,000--
2026-03-19Aranda Richard-20,000--
2026-03-19Aranda Richard-126,667--
2026-03-19Aranda Richard-157,500--
2026-03-19Aranda Richard-157,500--
2026-03-19Aranda Richard-162,500--
2026-03-19Aranda Richard-487,500--
2026-03-19Aranda Richard-572,000--
2026-03-19Aranda Richard-562,500--
2026-03-19Peterson Caryn+32,334--
2026-03-19Peterson Caryn+9,167--
2026-03-19Peterson Caryn+22,784--
2026-03-19Peterson Caryn+18,834--
2026-03-19Peterson Caryn+21,167--
2026-03-19Peterson Caryn+126,667--
2026-03-19Peterson Caryn+157,500--
2026-03-19Peterson Caryn+157,500--
2026-03-19Peterson Caryn+125,000--
2026-03-19Peterson Caryn+375,000--
2026-03-19Peterson Caryn+440,000--
2026-03-19Peterson Caryn+506,250--
2026-03-19Peterson Caryn-32,334--
2026-03-19Peterson Caryn-9,167--
2026-03-19Peterson Caryn-22,784--
2026-03-19Peterson Caryn-18,834--
2026-03-19Peterson Caryn-21,167--
2026-03-19Peterson Caryn-126,667--
2026-03-19Peterson Caryn-157,500--
2026-03-19Peterson Caryn-157,500--
2026-03-19Peterson Caryn-125,000--
2026-03-19Peterson Caryn-375,000--
2026-03-19Peterson Caryn-440,000--
2026-03-19Peterson Caryn-506,250--
2026-03-19Giraudo Bryan+96,667--
2026-03-19Giraudo Bryan+47,667--
2026-03-19Giraudo Bryan+60,000--
2026-03-19Giraudo Bryan+100,000--
2026-03-19Giraudo Bryan+176,667--
2026-03-19Giraudo Bryan+211,500--
2026-03-19Giraudo Bryan+211,500--
2026-03-19Giraudo Bryan+181,250--
2026-03-19Giraudo Bryan+543,750--
2026-03-19Giraudo Bryan+638,000--
2026-03-19Giraudo Bryan+693,750--
2026-03-19Giraudo Bryan-96,667--
2026-03-19Giraudo Bryan-47,667--
2026-03-19Giraudo Bryan-60,000--
2026-03-19Giraudo Bryan-100,000--
2026-03-19Giraudo Bryan-176,667--
2026-03-19Giraudo Bryan-211,500--
2026-03-19Giraudo Bryan-211,500--
2026-03-19Giraudo Bryan-181,250--
2026-03-19Giraudo Bryan-543,750--
2026-03-19Giraudo Bryan-638,000--
2026-03-19Giraudo Bryan-693,750--
2026-03-19Christian Waage+70,000--
2026-03-19Christian Waage+47,667--
2026-03-19Christian Waage+60,000--
2026-03-19Christian Waage+126,667--
2026-03-19Christian Waage+157,500--
2026-03-19Christian Waage+157,500--
2026-03-19Christian Waage+125,000--
2026-03-19Christian Waage+375,000--
2026-03-19Christian Waage+440,000--
2026-03-19Christian Waage+506,250--
2026-03-19Christian Waage-70,000--
2026-03-19Christian Waage-47,667--
2026-03-19Christian Waage-60,000--
2026-03-19Christian Waage-126,667--
2026-03-19Christian Waage-157,500--
2026-03-19Christian Waage-157,500--
2026-03-19Christian Waage-125,000--
2026-03-19Christian Waage-375,000--
2026-03-19Christian Waage-440,000--
2026-03-19Christian Waage-506,250--
2026-03-19Hasnain Faheem+43,500--
2026-03-19Hasnain Faheem+47,000--
2026-03-19Hasnain Faheem+325,000--
2026-03-19Hasnain Faheem+650,000--
2026-03-19Hasnain Faheem+544,500--
2026-03-19Hasnain Faheem+544,500--
2026-03-19Hasnain Faheem+437,500--
2026-03-19Hasnain Faheem+1,312,500--
2026-03-19Hasnain Faheem+1,540,000--
2026-03-19Hasnain Faheem+1,680,000--
2026-03-19Hasnain Faheem-43,500--
2026-03-19Hasnain Faheem-47,000--
2026-03-19Hasnain Faheem-325,000--
2026-03-19Hasnain Faheem-650,000--
2026-03-19Hasnain Faheem-544,500--
2026-03-19Hasnain Faheem-544,500--
2026-03-19Hasnain Faheem-437,500--
2026-03-19Hasnain Faheem-1,312,500--
2026-03-19Hasnain Faheem-1,540,000--
2026-03-19Hasnain Faheem-1,680,000--
2026-01-02Smith Robert Paul JR+562,500--
2026-01-02Smith Robert Paul JR+93,750--
2026-01-02Aranda Richard+562,500--
2026-01-02Aranda Richard+93,750--
2026-01-02Peterson Caryn+506,250--
2026-01-02Peterson Caryn+84,500--
2026-01-02Giraudo Bryan+693,750--
2026-01-02Giraudo Bryan+115,750--
2026-01-02Christian Waage+506,250--
2026-01-02Christian Waage+84,500--
2026-01-02Hasnain Faheem+1,680,000--
2026-01-02Hasnain Faheem+280,000--